Prostate Cancer

Leuvectin Phase II Trial Interim Data Presented

Published in Gene Therapy Weekly, October 19th, 2000

Vical Inc. (VICL), San Diego, California, announced interim results from an ongoing Phase II clinical trial testing Leuvectin, a gene-based immunotherapy in prostate cancer patients who have failed radiation therapy.

Failure of radiation therapy is usually detected through blood tests showing increasing levels of prostate-specific antigen (PSA), an indication of prostate cancer activity. Of the first six patients enrolled in this trial, all with rising PSA levels at the time they entered the trial, two have slowed or stopped their increase in serum PSA levels.

Treatments with Leuvectin also appear to be safe and well-tolerated, with no serious...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry